RT Journal Article
SR Electronic
T1 Fetal therapy model of myelomeningocele with three-dimensional skin using amniotic fluid cell-derived induced pluripotent stem cells
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 095281
DO 10.1101/095281
A1 Kazuhiro Kajiwara
A1 Tomohiro Tanemoto
A1 Seiji Wada
A1 Jurii Karibe
A1 Norimasa Ihara
A1 Yu Ikemoto
A1 Tomoyuki Kawasaki
A1 Yoshie Ohishi
A1 Osamu Samura
A1 Kohji Okamura
A1 Shuji Takada
A1 Hidenori Akutsu
A1 Haruhiko Sago
A1 Aikou Okamoto
A1 Akihiro Umezawa
YR 2016
UL http://biorxiv.org/content/early/2016/12/19/095281.abstract
AB Myelomeningocele (MMC) is a congenital disease without genetic abnormalities. Neurological symptoms are irreversibly impaired after birth. No effective treatment has been reported to date. Only surgical repairs have reported so far. In this study, we performed antenatal treatment of MMC with an artificial skin using induced pluripotent stem cells (iPSCs) generated from a patient with Down syndrome (AF-T21-iPSCs) and twin–twin transfusion syndrome (AF-TTTS-iPSCs) to a rat model. We manufactured three-dimensional skin with epidermis generated from keratinocytes derived from AF-T21-iPSCs and AF-TTTS-iPSCs and dermis of human fibroblasts and collagen type I. For generation of epidermis, we developed a novel protocol using Y-27632 and epidermal growth factor. The artificial skin was successfully covered over MMC defect sites during pregnancy, implying a possible antenatal surgical treatment with iPSC technology.